Diamyd tests preventative diabetes vaccine in high-risk children
This article was originally published in Scrip
Executive Summary
Diamyd has started a Phase II trial to examine whether the company's experimental vaccine, its lead candidate, which is also called Diamyd, is effective as a prophylactic treatment for children at high risk of developing diabetes. Diamyd is also in two Phase III trials in patients newly diagnosed with type 1 diabetes, an indication for which the Swedish company plans to submit an NDA in 2011.